Zacks: Brokerages Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$1.00 Per Share

Equities analysts predict that Akari Therapeutics PLC (NASDAQ:AKTX) will announce earnings per share of ($1.00) for the current quarter, according to Zacks. Zero analysts have issued estimates for Akari Therapeutics’ earnings. Akari Therapeutics reported earnings of ($0.08) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 1,150%. The firm is expected to report its next earnings results on Friday, March 30th.

On average, analysts expect that Akari Therapeutics will report full-year earnings of ($2.50) per share for the current fiscal year, with EPS estimates ranging from ($3.00) to ($2.00). For the next fiscal year, analysts expect that the firm will report earnings of ($2.00) per share, with EPS estimates ranging from ($3.00) to ($1.00). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Akari Therapeutics.

Akari Therapeutics (NASDAQ:AKTX) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.91.

A number of equities research analysts have commented on the company. ValuEngine raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Zacks Investment Research raised Akari Therapeutics from a “sell” rating to a “hold” rating and set a $5.00 target price for the company in a report on Monday, November 13th. Finally, B. Riley began coverage on Akari Therapeutics in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $6.38.

Several hedge funds have recently made changes to their positions in the company. AWM Investment Company Inc. purchased a new position in shares of Akari Therapeutics in the fourth quarter valued at $2,962,000. Millennium Management LLC increased its position in shares of Akari Therapeutics by 125.0% in the fourth quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 144,477 shares in the last quarter. Finally, Hikari Power Ltd increased its position in shares of Akari Therapeutics by 152.2% in the third quarter. Hikari Power Ltd now owns 151,334 shares of the biopharmaceutical company’s stock valued at $929,000 after buying an additional 91,322 shares in the last quarter. Institutional investors and hedge funds own 21.05% of the company’s stock.

Shares of Akari Therapeutics (AKTX) opened at $2.42 on Thursday. Akari Therapeutics has a fifty-two week low of $2.06 and a fifty-two week high of $22.20. The company has a market capitalization of $30.03, a price-to-earnings ratio of -8.64 and a beta of -9.00.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/zacks-brokerages-anticipate-akari-therapeutics-plc-aktx-will-announce-earnings-of-1-00-per-share.html.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply